New drug combo aims to shrink tumors before breast cancer surgery
NCT ID NCT07197697
Summary
This study is testing whether adding two new immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy helps shrink tumors before surgery in people with a specific type of breast cancer (HR+/HER2-). The goal is to see if this combination can completely eliminate cancer cells in the breast and lymph nodes by the time of surgery. Researchers will enroll 30 patients who haven't had prior treatment to evaluate both effectiveness and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.